Sequenom, Inc. (Nasdaq: SQNM) today announced the launch of the SensiGene(TM) Fetal RHD Genotyping test by Sequenom’s CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM). This is the company’s first laboratory developed test powered by its SEQureDx(TM) technology.

Illumina, Inc. (NASDAQ:ILMN) today announced its financial results for the fourth quarter and fiscal year of 2009. The company reported a revenue of $180.6 million, a 12% increase over the $160.9 million reported in the fourth quarter of 2008.

A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be available in the United States. Abbott’s ARCHITECT HE4 assay uses a simple blood test to help in monitoring for the recurrence or progression of epithelial ovarian cancer. If approved, this important immunoassay would be the first automated HE4 test available in the United States.

Luminex Corporation (Nasdaq: LMNX) today announced financial results for the fourth quarter and year ended December 31, 2009. Luminex achieved its highest ever quarterly consolidated revenue of $38.2 million, a 35 percent increase over the fourth quarter of 2008; full year 2009 revenue was $120.6 million, a 16 percent increase over 2008 during challenging economic conditions

Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results for the fourth quarter and fiscal year ended December 31, 2009. Total revenue for the fourth quarter was $88.8 million, as compared to total revenue of $78.6 million in the fourth quarter of 2008. In constant currency terms, revenue for the fourth quarter 2009 was positively impacted by $2.6 million as compared to 2008. For the full year 2009, total revenue was $327.1 million as compared to $410.2 million, which included a one-time intellectual property payment of $90 million, for 2008.

Millipore Corporation (NYSE:MIL), a leading provider of technologies, tools and services for the global life science industry, today reported financial results for its fourth quarter and full year ended December 31, 2009.

Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has entered into research agreements with The University of Pittsburgh Medical Center, Brigham and Women’s Hospital, the H. Lee Moffitt Cancer Center, Dartmouth’s Hitchcock Medical Center and the University of Sherbrooke to develop a microRNA-based diagnostic test to aid the detection of pancreatic cancer from fine-needle aspirate (FNA) biopsies.

Fluidigm Corporation today announced it has entered into a multi-year agreement with Bayer CropScience to supply integrated fluidic circuits (IFCs) and instrumentation to Bayer CropScience’s global operations. Bayer CropScience will be using Fluidigm technology to conduct marker-assisted breeding, genetic analysis in its molecular breeding program and quality control on its vegetable seeds.

Fluidigm, the inventor of integrated fluidic circuits (IFCs), has joined with IntegraGen SA, one of France’s leading providers of genetic research testing services, to bring IFC technology to French researchers. IntegraGen will offer premium class services to its customers using the Fluidigm BioMark™ System for Genetic Analysis and the Access Array™ sample preparation system for next-generation sequencing. IntegraGen’s lab will also be a demonstration site for researchers investigating Fluidigm’s technology.

An assay to aid in the early detection of HIV infection may soon be available in the United States. Abbott announced today it has submitted a Premarket Approval application for the ARCHITECT HIV Ag/Ab Combo assay to the U.S. Food and Drug Administration (FDA) for expedited review. Upon approval, the assay is expected to be the first test available in the United States to simultaneously detect the combined presence of HIV antigens (proteins produced by the HIV virus) and antibodies (proteins produced by the body to fight HIV antigens), which would allow for the early detection and ongoing monitoring of the virus.

DiaGenic ASA (OSL:DIAG) and Ferrer inCode today announced that they have signed a distribution agreement for the blood-based ADtect® test for early diagnosis of Alzheimer’s disease covering a total of 32 countries. The agreement gives Ferrer inCode, a biotech subsidiary of Grupo Ferrer Internacional, the exclusive right to sell and market ADtect® initially in Germany, Belgium, the Netherlands, Luxemburg, France, Italy, Spain and Portugal followed by Latin America.

Millipore Corporation (NYSE:MIL), a leading provider of technologies, tools and services for the global life science industry, today announced that it will disclose its financial results for the fourth quarter and fiscal 2009 on Tuesday, February 2, 2010, after the close of the stock market. The Company will webcast a conference call that evening to discuss its financial results, business outlook, and related corporate and financial matters. The call will begin at 4:45 p.m. Eastern Time and can be accessed through Millipore’s website at www.millipore.com.

Caprion Proteomics Inc. announced today that it has acquired from PPD, Inc. (Nasdaq: PPDI) the shares and assets of PPD Biomarker Discovery Sciences, LLC, PPD’s proteomics-based biomarker services division based in Menlo Park, Calif. The acquisition, which closed on December 31, 2009, further strengthens Caprion’s market leadership position in the area of proteomics biomarker services and will also broaden its client portfolio and revenue base. Financial terms of the acquisition were not disclosed.

Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2009 following the close of market on Thursday, February 4, 2010.
On the same day, at 2:00pm Pacific Time (5:00pm Eastern Time), Jay Flatley, president and chief executive officer, and Christian Henry, senior vice president, Corporate Development, and chief financial officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Agilent Technologies, Inc. (NYSE: A) and Varian, Inc. (NasdaqGS: VARI) today announced that they have been granted conditional antitrust clearance from the European Commission for Agilent’s proposed acquisition of Varian.